Jasper Therapeutics M&A Deal with Kira Pharmaceuticals
Jasper Therapeutics filed an amendment to provide required financial statements and pro forma information regarding its completed acquisition of Kira Pharmaceuticals. The deal involved the issuance of approximately 5.2 million common shares and 4.6 million preferred shares to Kira shareholders, alongside a concurrent $132 million private placement financing.
- Counterparty
- Kira Pharmaceuticals